This study evaluated the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma. The data showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) was the best treatment regimen in significantly improving overall survival and survival without cancer worsening in these patients.

This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these patients.

This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo) being the most effective in improving the overall survival of these patients.

This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax was safe and effective for these patients.

This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these patients.

This study compared the effectiveness of different antidepressant therapies on depression in patients with Parkinson’s disease (PD). The data showed that escitalopram (Cipralex), pramipexole (Mirapex), and repetitive transcranial magnetic stimulation (rTMS) were more effective than routine treatment in these patients. After 4 weeks, escitalopram showed better antidepressant effects and improved patients' quality of life and did not worsen motor function.

This study compared the effects of a Mediterranean versus a low-fat diet in the secondary prevention of major cardiovascular events (MACE) in patients with established coronary artery disease (CAD). The data showed that in secondary prevention, the Mediterranean diet was more effective in preventing MACEs compared to a low-fat diet in these patients.

This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients.

This study investigated the effectiveness and safety outcomes of adebrelimab (SHR-1316) plus carboplatin (Paraplatin) and etoposide (Etopophos)-based chemotherapy as first-line treatment for extensive-stage (ES) small-cell lung cancer (SCLC). The data showed that adebrelimab added to standard chemotherapy as first-line treatment significantly improved the overall survival with manageable side effects in these patients.

This study evaluated the effectiveness of tadalafil (Cialis) alone, silodosin (Rapaflo) alone, and the combination of both in the treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The data showed that a combination of tadalafil plus silodosin is more effective than either drug alone in treating LUTS in these patients.